Background: Vascular calcification is known to be a strong risk factor for cardiovascular
adverse events and mortality. Atherosclerosis, diabetes, aging, abnormal bone mineral …

Arterial calcification has been found to coexist with bone loss. Bisphosphonates, used as
standard therapy for osteoporosis, inhibit experimentally induced vascular calcification …

Background Epidemiologic and clinical data have suggested the existence of a biologic
linkage between the bone system and the vascular system. Bisphosphonates (BPs) are …

Theoretically bisphosphonates could accelerate or retard vascular calcification. In subjects
with low GFR, the position is further confounded by a combination of uncertain …

Vascular calcification is common in patients with advanced chronic kidney disease and is
associated with poorer outcomes. Although the pathophysiology is not completely …

The increasing knowledge on bone calcification processes has revealed some similarities
with vascular tissue, where calcifications of arteries and cardiac valves contribute to several …

Calcification presents important clinical implications in cardiovascular diseases, especially
in coronary arteries. Epidemiological evidence has shown the coexistence of vascular …

Chronic kidney disease (CKD) is thought to affect approximately one in 10 people. Patients
with CKD have significantly increased cardiovascular morbidity and mortality in comparison …

Vascular calcification or ectopic mineralization in blood vessels is an active, cell-regulated
process, increasingly recognized as a general cardiovascular risk factor. Ectopic artery …

Although it is known that bisphosphonates prevent medial vascular calcification in vivo, their
mechanism of action remains unknown and, in particular, whether they act directly on the …